Coriolis Pharma, a provider of formulation research and development services for biopharmaceuticals and vaccines, has opened its new ATMP development facilities under biosafety level S2 (BSL2 / S2). After one year of re-construction, the new facilities in close proximity to Coriolis’ headquarters in Martinsried will increase Coriolis’ capabilities for ATMP development. Formulation development for ATMPs, including cell culture activities, particle characterization, particle identification and ...